MétaCan
Menu
Back to cohort
Record W4226208111 · doi:10.47326/ocsat.cpg.2022.10.0

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19

2022· report· en· W4226208111 on OpenAlexaboutno aff

Bibliographic record

Venuenot available
Typereport
Languageen
FieldMedicine
TopicPharmaceutical studies and practices
Canadian institutionsnot available
Fundersnot available
KeywordsGuidelineCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakClinical PracticeIntensive care medicineVirologyFamily medicineInternal medicinePathologyInfectious disease (medical specialty)OutbreakDisease

Abstract

fetched live from OpenAlex

Therapeutic Management of Adult Patients with COVID-19Recommendations apply to patients >18 years of age.Recommendations are based on the best available data and may change as additional data becomes available.Science Briefs can be found on the Ontario COVID-19 Science Advisory Table website. RECOMMENDATIONSDexamethasone 6 mg PO/IV daily for 10 days (or until discharge if sooner) is recommended.Tocilizumab is recommended for patients who are on recommended doses of dexamethasone therapy (or a dose-equivalent corticosteroid) AND are within 14 days of hospital admission (or within 14 days of a new COVID-19 diagnosis if the infection was nosocomially acquired). RECOMMENDATIONS FOR DRUG SHORTAGE SITUATIONSIn drug shortage situations, a single dose of tocilizumab 400 mg IV or sarilumab 400 mg IV should be used for all eligible patients.A second dose of tocilizumab or sarilumab should not be given to any patient.Baricitinib 4 mg PO/NG daily for 14 days (or until discharge if sooner) is recommended in patients who are on recommended doses of dexamethasone therapy (or a dose-equivalent corticosteroid) or who have a contraindication to corticosteroid treatment.The panel does not recommend combined use of baricitinib and IL-6 inhibitors due to absence of safety and efficacy evidence.Dexamethasone 12 mg PO/IV daily for 10 days (or until discharge if sooner) may be considered in patients who are unable to receive IL-6 inhibitors (tocilizumab, sarilumab) or baricitinib.This recommendation is based on very low certainty evidence of reduction in days alive without life support, and the need for inpatient treatment options with a reasonable safety profile during an anticipated spike in COVID-19 cases due to the Omicron variant and widespread shortages of IL-6 inhibitors and baricitinib.Prophylactic dose low molecular weight or unfractionated heparin is recommended.These patients should not receive therapeutic dose anticoagulation unless they have a separate indication for this treatment.Remdesivir is not recommended for patients receiving mechanical ventilation.Remdesivir 200 mg IV on day 1, then 100 mg IV daily for 4 days may be considered in patients requiring high-flow oxygen (i.e., oxygen by mask, oxygen by high-flow nasal cannula, or non-invasive mechanical ventilation).SARS-CoV-2 neutralizing antibodies are not recommended for critically ill patients.For symptomatic inpatients with nosocomial infection, see mildly ill recommendations for sotrovimab on page 2.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.027
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.750
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0050.027
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.174
GPT teacher head0.514
Teacher spread0.340 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractyes

Explore more

Same topicPharmaceutical studies and practicesFrench-language works237,207